Summary
TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% – Here’s Why
TuHURA Biosciences, Inc. (NASDAQ: HURA - Get Free Report) dropped 3.1% on Friday. The stock traded as low as $1.87 and last traded at $1.90. Approximately 939,185 shares changed hands during trading, a decline of 17% from the average daily volume of 1,127,606 shares. The stock had previously closed at $1.96. Wall Street Analyst Weigh
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) Entered into a non-binding letter of intent with Kineta regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 expanding its pipeline with a Phase 2 ready, novel VISTA inhibiting antibody Advancing IFx-3.0, the first systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell Lymphoma Early discovery programs designing first-in-class tumor microenvironment modulating bi-specific antibody drug conjugates (ADCs) or peptide drug conjugates (PDCs) targeting Myeloid Derived Suppressor Cells (MDSCs) Company expands leadership team with key clinical and regulatory appointments to drive strategy and operational execution TAMPA, FL / ACCESSWIRE / November 25, 2024 / TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided a business update and outlined upcoming targeted milestones. "We have made significant progress toward accomplishing our 2024 corporate objectives, including reaching a Special Protocol Assessment agreement with the FDA by working with the Oncology Center of Excellence (OCE) and FDA's Project Front Runner initiative for a novel Phase 3 trial design for IFx-2.0 under the FDA's accelerated approval pathway.
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC. As part of the event, Dr. James Bianco, President and Chief Executive Officer of TuHURA participated in the Precision and Immune Oncology panel.
TuHURA Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $1.79 | $2.3 | $0.51 | 28.49% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1 | $1.79 | $2.29 | $0.5 | 27.93% |
| BG Bart Gancher Intech Investment Management LLC | 12,379 | $27,032.05 | $28,336.77 | $1,304.72 | 4.83% |
| DM Dipen Mehta Invst LLC | 42,506 | $83,413.54 | $98,826.45 | $15,412.91 | 18.48% |
 Joseph Castro Nuveen LLC | 33,575 | $74,872 | $78,135.74 | $3,263.74 | 4.36% |
TuHURA Biosciences, Inc. (HURA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has TuHURA Biosciences, Inc. ever had a stock split?
TuHURA Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | James A. Bianco CEO | NASDAQ (CM) Exchange | 898920103 CUSIP |
| US Country | 19 Employees | - Last Dividend | 18 Oct 2024 Last Split | - IPO Date |
Overview
TuHURA Biosciences, Inc. is a pioneering immuno-oncology company located in Tampa, FL, that is entering a critical phase in its journey to bring innovative cancer treatments to patients. Being in a phase 3 registration-stage indicates a pivotal point in clinical development, signifying that its novel technologies are under the final stages of clinical trials, assessing their effectiveness and safety for human use. TuHURA Biosciences is dedicated to developing breakthrough technologies designed to overcome resistance to cancer immunotherapy. This focus is crucial as resistance to current treatments poses a significant hurdle in cancer care, limiting the efficacy and benefits of immunotherapy for many patients. Through its commitment to innovation and progress in cancer treatment, TuHURA Biosciences aims to make a substantial impact on the lives of individuals battling cancer.
Products and Services
- Novel Technologies to Overcome Cancer Immunotherapy Resistance
This core focus of TuHURA Biosciences involves the development of advanced technologies aiming to circumvent the mechanisms that lead to resistance against existing cancer immunotherapies. By understanding and targeting the root causes of immunoresistance, these novel technologies offer the potential to enhance the effectiveness of cancer treatments, thereby improving patient outcomes.
